VelaVigo

Chinese biotech funding backed by venture capital and private equity firms experienced a much-needed uplift over the past few weeks, thanks partly to investor interest in assets with novel modalities

Antibody-drug conjugate (ADC) developer Adcendo has been busy during the last year and a half since the company raised a €31m ($32.3m) extension of the €51m ($53.2m) series A it originally raised in 2

BioNTech’s close to $1bn acquisition of Biotheus announced earlier this month marked another big M&A deal between a Chinese biotech and a foreign firm following AstraZeneca’s roughly $1.2bn buyou

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Otsuka Pays $10m Up Front For Ion